FENC
Fennec Pharmaceuticals Inc

1,302
Mkt Cap
$341.77M
Volume
67,618.00
52W High
$9.92
52W Low
$3.96
PE Ratio
-21.10
FENC Fundamentals
Price
$8.96
Prev Close
$8.72
Open
$8.87
50D MA
$8.83
Beta
0.85
Avg. Volume
82,508.86
EPS (Annual)
-$0.016
P/B
-33.30
Rev/Employee
$1.49M
Loading...
Loading...
News
all
press releases
Are Options Traders Betting on a Big Move in Fennec Pharmaceuticals Stock?
Investors need to pay close attention to FENC stock based on the movements in the options market lately.
Zacks·2d ago
News Placeholder
More News
News Placeholder
New Strong Sell Stocks for Oct. 15th
FENC, BABA and ALCO have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2025.
Zacks·9d ago
News Placeholder
Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last?
Day One Biopharmaceuticals (DAWN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·18d ago
News Placeholder
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
Investors need to pay close attention to Adherex Technologies stock based on the movements in the options market lately.
Zacks·1mo ago
News Placeholder
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates
Adherex Technologies (FENC) delivered earnings and revenue surprises of -83.33% and +1.76%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of +5.88% and +2.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.77% and +47.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +21.74% and -71.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Concentra Group (CON) Matches Q2 Earnings Estimates
Concentra (CON) delivered earnings and revenue surprises of 0.00% and +2.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
Here is how Editas Medicine (EDIT) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
Zacks·3mo ago

Latest FENC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.